ArticleAnnals of internal medicine2020
Clinical Validity of Serum Antibodies to SARS-CoV-2 : A Case-Control Study.
Article in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Epidemiological, Radiographical, and Laboratorial Characteristics of Chinese Asymptomatic Cases With COVID-19: A Systematic Review and Meta-Analysis.Frontiers in public health · 2022Pooled it
- Global prevalence and pathogenesis of headache in COVID-19: A systematic review and meta-analysis.F1000Research · 2020Pooled it
- Medical education during the COVID-19 pandemic: a reflection on the JHUSOM experience.BMC medical education · 2024Observational
- Article
- Impact of methotrexate on humoral and cellular immune responses to SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis.Clinical and experimental medicine · 2023Article
- Medical Education during the COVID-19 Pandemic: A Reflection on the JHUSOM Experience.Research square · 2023Article
- Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.Arthritis care & research · 2023Article
- Comparative Longitudinal Serological Study of Anti-SARS-CoV-2 Antibody Profiles in People with COVID-19.Microorganisms · 2023Article
- Association of healthcare worker behaviors with coronavirus disease 2019 (COVID-19) risk during four pandemic periods and characteristics associated with high-risk behaviors.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Nine-month course of SARS-CoV-2 antibodies in individuals with COVID-19 infection.Irish journal of medical science · 2022Article
- Neutralizing SARS-CoV-2 Spike Antibodies against Omicron in Paired Samples after Two or Three Doses of mRNA Vaccine.Microbiology spectrum · 2022Article
- Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.Blood advances · 2022Article
- Characteristics of SARS-CoV-2 Seropositivity among Emergency Department Healthcare Workers at a Tertiary Care Center in Baltimore.Healthcare (Basel, Switzerland) · 2022Article
- High Viral Specific Antibody Convalescent Plasma Effectively Neutralizes SARS-CoV-2 Variants of Concern.medRxiv : the preprint server for health sciences · 2022Article
- Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals.medRxiv : the preprint server for health sciences · 2022Article
- A Longitudinal Analysis of SARS-CoV-2 Antibody Responses Among People With HIV.Frontiers in medicine · 2022Article
- Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals.PloS one · 2022Article
- Nationwide increases in anti-SARS-CoV-2 IgG antibodies between October 2020 and March 2021 in the unvaccinated Czech population.Communications medicine · 2022Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical utility of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies remains undefined.
objectiveTo determine the clinical validity and utility of SARS-CoV-2 antibodies.
designCase-control study.
settingFirst month of testing for coronavirus disease 2019 (COVID-19) by using a nucleic acid amplification test (NAAT) on nasopharyngeal swabs at the Johns Hopkins Hospital, Baltimore, Maryland (11 066 persons).
participantsOf the 11 066 tested persons, 115 (1%) were hospitalized adults investigated for COVID-19. Clinical record review was performed to classify them into a COVID-19 case group ( MEASUREMENTS: Serum IgG and IgA antibodies against SARS-CoV-2 spike protein were detected by using enzyme-linked immunosorbent assay.
resultsSensitivity and specificity of the SARS-CoV-2 IgG assay were 0.976 (95% CI, 0.928 to 0.995) and 0.988 (CI, 0.974 to 0.995), respectively, when performed 14 days or later after symptom onset, but sensitivity decreased at earlier time points. Immunoglobulin G developed rapidly and was sustained at high levels throughout follow-up (up to 58 days). Antibodies to SARS-CoV-2 predicted the odds of developing acute respiratory distress syndrome, which increased by 62% (CI, 48% to 81%; LIMITATIONS: The study was retrospective and performed at a single center; the sample was small; follow-up was limited; and selection bias may have occurred.
conclusionAntibodies to SARS-CoV-2 demonstrate infection when measured at least 14 days after symptom onset, are associated with clinical severity, and provide valuable diagnostic support in patients who test negative by NAAT but remain clinically suspicious for COVID-19. PRIMARY FUNDING SOURCE: Clinical Immunology Laboratory, Department of Pathology, Johns Hopkins Hospital.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.